Denali Therapeutics, Sanofi initiate dosing in DNL747 trial

Denali Therapeutics (DNLI) announced initiation of dosing in a Phase 1b clinical study of DNL747 in patients with ALS, in collaboration with its partner Sanofi (SNY). RIPK1, receptor-interacting serine/threonine-protein kinase 1, is a signaling protein in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body. Denali, together with its partner Sanofi, is investigating several molecules targeting RIPK1 for multiple indications, including DNL747 for ALS.
https://thefly.com/landingPageNews.php?id=2845507